Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zecdarasib + folinic acid + fluorouracil + irinotecan + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
The combination of zecdarasib (INCB161734) with folinic acid, fluorouracil, irinotecan, and oxaliplatin is an investigational antineoplastic regimen designed to treat KRAS G12D-mutated malignancies, particularly pancreatic ductal adenocarcinoma (PDAC). Zecdarasib is a novel, selective, oral small molecule ON/OFF inhibitor that targets both the active (GTP-bound) and inactive (GDP-bound) states of the mutant KRAS G12D protein, thereby blocking downstream oncogenic signaling pathways such as RAF-MEK-ERK and PI3K-AKT. The chemotherapy backbone, known as modified FOLFIRINOX (mFOLFIRINOX), consists of oxaliplatin (a DNA cross-linking agent), irinotecan (a topoisomerase I inhibitor), and fluorouracil (an antimetabolite whose thymidylate synthase inhibition is biochemically enhanced by folinic acid). Developed by Incyte, this combination regimen is being evaluated in Phase 1 and Phase 3 clinical trials to improve survival outcomes in patients with advanced or metastatic KRAS G12D-mutated solid tumors.
- Other names
- INCB161734 + folinic acid + fluorouracil + irinotecan + oxaliplatinINCB161734 + mFOLFIRINOXINCB161734 + modified FOLFIRINOXzecdarasib + mFOLFIRINOXzecdarasib + modified FOLFIRINOX
02
Targets
DNATOP1 (DNA Topoisomerase I)KRAS (Kirsten rat sarcoma viral oncogene homolog)TS (Thymidylate synthase)
Beyond the preview
Go deeper on zecdarasib + folinic acid + fluorouracil + irinotecan + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zecdarasib + folinic acid + fluorouracil + irinotecan + oxaliplatin.